Clopidogrel in High-risk Patients With Acute Non-disabling Cerebrovascular Events
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of a 3-month regimen of clopidogrel
initiated with a loading dose (LD) of 300 mg followed by 75 mg/day during the first 21days
versus a 3-month regimen of ASA 75 mg/day alone on reducing the 3-month risk of any stroke
(both ischemic and hemorrhagic, primary outcome) when initiated within 24 hours of symptom
onset in high-risk patients with TIA or minor stroke.